Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Calza L, Trapani F, Salvadori C, Magistrelli E, Manfredi R, Colangeli V, Di Bari MA, Borderi M, Viale P. Calza L, et al. Among authors: magistrelli e. Scand J Infect Dis. 2013 Feb;45(2):147-54. doi: 10.3109/00365548.2012.712213. Epub 2012 Sep 19. Scand J Infect Dis. 2013. PMID: 22991923
Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
Calza L, Manfredi R, Colangeli V, Trapani FF, Salvadori C, Magistrelli E, Danese I, Verucchi G, Serra C, Viale P. Calza L, et al. Among authors: magistrelli e. AIDS Res Hum Retroviruses. 2013 Mar;29(3):547-56. doi: 10.1089/aid.2012.0015. Epub 2012 Oct 25. AIDS Res Hum Retroviruses. 2013. PMID: 23098891 Clinical Trial.
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Calza L, Magistrelli E, Danese I, Colangeli V, Borderi M, Bon I, Re MC, Mancini R, Conti M, Motta R, Viale P. Calza L, et al. Among authors: magistrelli e. Curr HIV Res. 2016;14(1):61-70. doi: 10.2174/1570162x1401151102143222. Curr HIV Res. 2016. PMID: 26531764
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L, Danese I, Magistrelli E, Colangeli V, Manfredi R, Bon I, Re MC, Conti M, Viale P. Calza L, et al. Among authors: magistrelli e. HIV Clin Trials. 2016 Feb;17(1):38-47. doi: 10.1080/15284336.2015.1122874. Epub 2016 Jan 5. HIV Clin Trials. 2016. PMID: 26728706
21 results